UB
MRTX

UMB Bank’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

UMB Bank’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-23
Closed -$2K – 2066
2022
Q1 		$2K Sell
23
-120
-84% -$12.3K ﹤0.01% 1867
2021
Q4 		$21K Buy
+143
New +$22.2K ﹤0.01% 1269

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

UMB Bank's MRTX Position: Q2 2022 in Review

UMB Bank sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2022, closing a stake of 23 shares — an estimated $2K sold.

UMB Bank first reported a position in MRTX in Q4 2021 and held it in 2 quarters. The position peaked at $21K in Q4 2021. 230 funds tracked by Wall St. Rank hold MRTX as of Q2 2022.

  • UMB Bank reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • UMB Bank sold 23 Mirati Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $2K.
  • UMB Bank first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • UMB Bank's Mirati Therapeutics, Inc. Common Stock position peaked at $21K in Q4 2021.
  • 230 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2022.

Based on UMB Bank's 13F filing for Q2 2022, filed 20 Jul 2022.